Eligibility
ascites, malignancy, Tumors, intestinal pneumonitis, infection, cardiac, hepatic or renal failure, hypersensitivity
HEPATITIS B, BRAIN METASTASIS, PLEURAL EFFUSION, ASCITES, PULMONARY FIBROSIS, PERIPHERAL SENSORY NEUROPATHY, RECURRENT DISEASE, TUMORS, INFECTION, JC VIRUS INFECTION, ONCOLOGY, HYPERSENSITIVITY
Inclusion criteria were as follows: 1) histologically or cytologically proven BTC; 2) advanced or recurrent disease; 3) no prior chemotherapy or radiotherapy except for adjuvant chemotherapy, which had been completed at least 6 months before enrollment; 4) Eastern Cooperative Oncology Group (ECOG) performance status of 0–1; 5) age of 20–75 years; 6) At least one measurable lesion on computed tomography (CT) or magnetic resonance imaging (MRI) defined by Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1); 7) adequate organ function, as indicated by white blood cell count ≤ 10,000 /mmThe exclusion criteria were as follows: 1) active concomitant malignancy; 2) hypersensitivity to iodine and gadolinium contrast; 3) brain metastasis; 4) blood infusion or hematopoietic growth factor use within 7 days before enrollment; 5) uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms of homozygous UGT1A1*28 or UGT1A1*6 or heterozygous UGT1A1*6 and UGT1A1*28; 6) marked pleural effusion, or ascites active within 14 days before enrollment; 7) severe comorbidities, such as cardiac, hepatic or renal failure; 8) pulmonary fibrosis or intestinal pneumonitis; 9) grade 2 or higher peripheral sensory neuropathy; 10) active infection other than hepatitis B or C virus infection; 11) user of atazanavir sulfate; 12) pregnant or lactating woman; and 13) disqualified for trial judged by clinical investigators.